CNS specific amniotic mesenchymal stem cell therapy - Amniotics
Alternative Names: CogniStem ™Latest Information Update: 09 Feb 2024
At a glance
- Originator Amniotics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Neurodegenerative disorders; Parkinson's disease
- No development reported Spinal muscular atrophy
Most Recent Events
- 09 Feb 2024 No development reported for Spinal muscular atrophy (In children) in Sweden (unspecified route) (Amniotics pipeline, February 2024)
- 09 Feb 2024 Preclinical trials in Alzheimer's disease in Sweden (parenteral) (Amniotics pipeline, February 2024)
- 09 Feb 2024 Preclinical trials in Amyotrophic lateral sclerosis in Sweden (parenteral) (Amniotics pipeline, February 2024)